ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
2.930
-0.290 (-9.01%)
Oct 28, 2025, 10:42 AM EDT - Market open
ProKidney Employees
ProKidney had 204 employees as of December 31, 2024. The number of employees increased by 41 or 25.15% compared to the previous year.
Employees
204
Change (1Y)
41
Growth (1Y)
25.15%
Revenue / Employee
$2,583
Profits / Employee
-$355,265
Market Cap
862.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 204 | 41 | 25.15% |
| Dec 31, 2023 | 163 | 76 | 87.36% |
| Dec 31, 2022 | 87 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PROK News
- 8 days ago - ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025 - GlobeNewsWire
- 5 weeks ago - ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy - Seeking Alpha
- 7 weeks ago - ProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 2 months ago - ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewsWire
- 3 months ago - ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel - GlobeNewsWire
- 3 months ago - ProKidney: What's Happening With PROK Stock? - Forbes